MICB and cancer: Asking for the therapeutic value of MICB, Ferrari de Andrade et al. found that MICB a3 domain-specific antibodies substantially increased the density of the stimulatory MICB ligands on the surface of cancer cells, reduced shed MICB amounts, and induced NK cell attack against cancer cells (Andrade 2018).